Latigo IPO raises nearly $350M for pain drug development
The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.